Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris' (PHVS) Investment Narrative? [Yahoo! Finance]
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: Yahoo! Finance
Alongside these results, the company highlighted progress in its hereditary angioedema pipeline, including completed Phase 3 enrollment and confirmed plans to file a New Drug Application for deucrictibant immediate-release in the first half of 2026. We will now examine how Pharvaris's completed Phase 3 enrollment for deucrictibant shapes the company's broader investment narrative and risk profile. Outshine the giants: these 21 early-stage AI stocks could fund your retirement What Is Pharvaris' Investment Narrative? To own Pharvaris today, you have to believe that its deucrictibant franchise can eventually justify years of zero revenue and steadily rising losses, including the recent €175.7 million annual net loss. The completed Phase 3 enrollment for the CHAPTER-3 prophylaxis study matters because it locks in a clear sequence of near-term catalysts around deucrictibant: the planned New Drug Application filing for the immediate-release, on-demand capsule in the first half of 2
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference [Yahoo! Finance]Yahoo! Finance
- Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 ConferenceGlobeNewswire
- Pharvaris (PHVS) had its "buy" rating reaffirmed by Citigroup Inc..MarketBeat
- Pharvaris (PHVS) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PHVS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "stMarketBeat
- Pharvaris (PHVS) was upgraded by Wolfe Research to "strong-buy".MarketBeat
PHVS
Earnings
- 4/2/26 - Miss
PHVS
Sec Filings
- 4/16/26 - Form 144
- 4/14/26 - Form 4
- 4/10/26 - Form 4
- PHVS's page on the SEC website